Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.

EP: 1.The Role of the HER2 Receptor in Breast Cancer

EP: 2.Necessary Tests After a Diagnosis of Breast Cancer

EP: 3.Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

EP: 4.Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist

EP: 5.Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

EP: 6.Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

Now Viewing

EP: 7.Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

EP: 8.How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

EP: 9.Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

EP: 10.Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP: 11.Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Related Videos

Related Content

Advertisement

December 20th 2024

Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset

Ariana Pelosci

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

December 17th 2024

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

Tim Cortese

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

December 16th 2024

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

Kristi Rosa

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

December 13th 2024

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

Jason Broderick

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

Related Content

Advertisement

December 20th 2024

Zejula-Jemperli Combo Shows Promising Responses in Breast Cancer Subset

Ariana Pelosci

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

December 17th 2024

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

Tim Cortese

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

December 16th 2024

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

Kristi Rosa

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

December 13th 2024

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

Jason Broderick

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.